Stromal cell-derived factor 1α (SDF-1α): A marker of disease burden in patients with atrial fibrillation

OBJECTIVES: Stromal cell-derived factor 1a (SDF-1α), is a chemokine and is able to home hematopoietic progenitor cells to injured areas of heart tissue for structural repair. Previous studies have found increased levels of SDF-1α in several cardiac diseases, but only few studies have investigated SDF-1α in patients with atrial fibrillation (AF). We aimed to test SDF-1α in a large cohort of patients with AF and its role as a prognostic marker Design: Between January 1st 2008 to December 1st 2012, 290 patients with ECG documented AF were enrolled from the in- and outpatient clinics at the Department of Cardiology, Copenhagen University Hospital, Hvidovre, Denmark. Plasma levels of SDF-1α were measured using ELISA technique. Clinical data were registered and patient follow-up was conducted.

RESULTS: Patients with permanent AF had significantly higher SDF-1α levels (2199.5 pg/ml) than patients with paroxysmal AF (1982.0 pg/ml) and persistent AF (1906.0 pg/ml), p<0.0005. Higher SDF-1α level was associated with longer time spent in the hospital per readmission, p<0.05.

CONCLUSION: In AF patients, a higher SDF-1α level was found in patients with a more progressive state of arrhythmia and was associated with longer hospitalizations. These findings suggest that SDF-1α could prove valuable in risk stratification and evaluating the disease burden in AF patients.